Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Ephraim Mcdowell Regional Medical Center Unveils Xenex Germ Killing Robot - Yahoo Finance

click here.

Cleanint Rolls Out Cleanstethoscope and Cleanhands to Largest Medical Transportation Company in the Nation - Yahoo Finance

AMR Cleanstethoscope The Xenex robot is capable of moving throughout the hospital destroying highly contagious germs such as MRSA, C.diff , and even the Ebola virus. This investment in patient safety and care has been funded through the generosity of the Ephraim McDowell Health Care Foundation. Recognized by Beckers Hospital Review as one of the 100 Great Community Hospitals in America, the use mrsa pregnancy of the Xenex robot at EMRMC reinforces its commitment to patient safety and quality care. No other public hospital in the commonwealth uses such sophisticated medical technology to ensure the patients, staff and visitors have reduced exposure to dangerous bacteria that cause infections requiring expensive and lengthy hospital care. Through the use of high-intensity pulsed xenon ultraviolet light, the Xenex germ-zapping robot quickly destroys the DNA of these contagions. The Ephraim McDowell Health Care Foundation has funded nearly $1.8 million in health care needs in just the past three years. This current donation to the medical center further demonstrates to those who charitably support the growth of health care services through the Foundation that critical needs are being funded.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/ephraim-mcdowell-regional-medical-center-214300261.html

SNGX: Updated Preclinical Data on RiVax Presented - Yahoo Finance

For more information, please visit www.viadermalicensing.com . Forward Looking Statements This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/viaderma-inc-initiate-upcoming-field-141701919.html

ViaDerma, Inc., to Initiate Upcoming Field Trial of Comparison for Onychomycosis - Yahoo Finance

Let your gloves air dry instead of keeping them balled up in your pockets. 2. Wash gloves often.
For the original version including any supplementary images or video, visit http://abcnews.go.com/US/avoid-germs-winter-gloves/story?id=29242416

DISC Sports & Spine Center Taps Dr. Dean K. Matsuda to Launch Hip Arthroscopy Center of Excellence

As a former athlete myself, I have seen both sides of the scalpel, and it has been my career-long goal to further this area of sports medicine into new levels of patient care. Dr. Matsuda, who serves as chairman of the Sports Medicine and Arthroscopy program committee for the American Academy of Orthopaedic Surgeons, comes to DISC after 26 years at Kaiser West Los Angeles Medical Center, where he developed the sports medicine program. During that time, he was the chief of orthopedics, the director of sports medicine, and was honored as the very first surgeon of any field to receive the Distinction Merit Award for Surgical Excellence and Innovation.
For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/03/prweb12550912.htm

AMR will be purchasing 50,000 AMR-branded Cleanstethoscope and Cleanhands units to be used by field personnel. Founded in 2009, Cleanint began with a singular concept: it's simple it's clean. This principle is at the heart of everything we develop. It means innovative products that perform flawlessly without getting in your way. It means practical solutions to let people work and play with complete peace of mind. It means learning from our customers how we can improve the quality of their lives through thoughtful designs.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cleanint-rolls-cleanstethoscope-cleanhands-largest-140000295.html

How to Avoid the Germs on Your Winter Gloves - ABC News

With these two distinctive anti-melioidosis programs, Soligenix is emerging as a key player in this specific field. There is still Room for Further Price Appreciation We maintain an Outperform rating for Soligenix and keep our 12-month price target of $5.50 per share. We believe there is still enough room for further price appreciation. Soligenix becomes a late development stage biotech company through the acquisition of SGX301, a Phase III candidate for CTLC. Soligenix is focused on cancer/cancer supportive care and GI disorders, two large pharmaceutical markets both in the US and around the world. Soligenix also develops vaccines/oral therapeutics for biodefense. In addition to SGX301, Soligenix has built a diversified pipeline using three proprietary platform technologies: the SGX942 platform, the oral BDP platform and the ThermoVax platform.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/sngx-updated-preclinical-data-rivax-172500607.html

Don't be the product, buy the product!